3SBio Secures Exclusive Rights for Cancer Drug
Company Announcements

3SBio Secures Exclusive Rights for Cancer Drug

3SBio (HK:1530) has released an update.

3SBio’s subsidiary, Shenyang Sunshine, has entered into a strategic agreement with Haihe Biopharma to exclusively commercialize Paclitaxel Oral Solution in Mainland China and Hong Kong. This collaboration involves Shenyang Sunshine making initial and milestone payments to RMX Biopharma, which will continue overseeing clinical trials and development. Investors are advised to remain cautious as the product’s successful commercialization is not guaranteed.

For further insights into HK:1530 stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks HongKong Auto-Generated Newsdesk3SBio Issues Supplemental Share Grant Info
TipRanks HongKong Auto-Generated Newsdesk3SBio Awards Shares to Top Performers
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App